Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Amortization of Deferred Charges (2021 - 2023)

AVITA Medical's Amortization of Deferred Charges history spans 3 years, with the latest figure at $86000.0 for Q4 2023.

  • For Q4 2023, Amortization of Deferred Charges rose 1.18% year-over-year to $86000.0; the TTM value through Dec 2023 reached $341000.0, up 0.89%, while the annual FY2023 figure was $341000.0, 0.89% up from the prior year.
  • Amortization of Deferred Charges reached $86000.0 in Q4 2023 per RCEL's latest filing, up from $85000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $86000.0 in Q4 2023 to a low of $50000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 3 years is $81000.0, with a median of $85000.0 recorded in 2022.
  • Peak YoY movement for Amortization of Deferred Charges: soared 70.0% in 2022, then changed 0.0% in 2023.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $82000.0 in 2021, then rose by 3.66% to $85000.0 in 2022, then increased by 1.18% to $86000.0 in 2023.
  • Per Business Quant, the three most recent readings for RCEL's Amortization of Deferred Charges are $86000.0 (Q4 2023), $85000.0 (Q3 2023), and $85000.0 (Q2 2023).